Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX131 · 2 trials · 8 indications
For all cohorts: Incidence of Adverse events defined as dose-limiting toxicities
Phase 2 (expansion of selected Phase 1 disease types)
Phase 2 (expansion of selected Phase 1 disease types)
Defined as dose-limiting toxicities
ORR based on Independent Review Committee (IRC) assessment, defined as the proportion of subjects who have achieved a best overall response of CR or PR according to appropriate response evaluation criteria for each disease histology
| Arm | Type | Description |
|---|---|---|
| CTX131 | EXPERIMENTAL | Administered by IV infusion following lymphodepleting chemotherapy |
| Name | Type | Description |
|---|---|---|
| CTX131 | BIOLOGICAL | CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components |
Inclusion Criteria: 1. ≥18 years of age 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (ECOG status of 2 will be permitted for subjects with AML) 3. Diagnosed with r/r T Cell Lymphoma (TCL), B Cell Lymphoma (BCL), or Acute Myeloid Leukemia (AML) T cell lymphoma, including St...
CTX131 is an investigational monoclonal antibody developed by CRISPR Therapeutics AG that targets CD70. It is being studied in Phase 1 clinical trials for the treatment of clear cell renal cell carcinoma and T cell lymphoma, as well as other hematologic and solid tumor malignancies.
CTX131 is being evaluated for the treatment of clear cell renal cell carcinoma and T cell lymphoma. Clinical trials have also included patients with B cell lymphoma, acute myeloid leukemia, cervical carcinoma, esophageal carcinoma, pancreatic adenocarcinoma, and malignant pleural mesothelioma.
CTX131 targets CD70, a protein expressed on certain hematologic and solid tumor cells. By binding to CD70, CTX131 is designed to direct an immune response against CD70-positive cancer cells. This mechanism is under investigation in Phase 1 trials.
CTX131 is being developed by CRISPR Therapeutics AG, a biopharmaceutical company traded on the Nasdaq under the ticker symbol CRSP. The company is responsible for the clinical development of CTX131.
CTX131 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA or any regulatory agency. The Phase 1 trials have been completed, and further studies may be planned.
CTX131 has been studied in two completed Phase 1 trials: NCT05795595 in relapsed or refractory solid tumors, including clear cell renal cell carcinoma, and NCT06492304 in relapsed or refractory hematologic malignancies, including T cell lymphoma. Both trials enrolled adult participants.